Annual report pursuant to Section 13 and 15(d)

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS

v3.19.2
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS
12 Months Ended
Apr. 30, 2019
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]  
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS

PHARMACYTE BIOTECH, INC.

SCHEDULE II — VALUATION AND QUALIFYING ACCOUNTS

Years Ended April 30, 2019 and 2018 

 

 

 

Description

  Balance at
Beginning of
Year
    Additions
Charged to
Costs and
Expenses
    Charged to
Other
Accounts
    Deductions     Balance at
End of Year
 
Reserve Deducted in the Balance Sheets from the Asset to which it applies:                                        
Allowance for Deferred Tax Assets                                        
Year ended April 30, 2019   $ 13,235,601             952,170             14,187,771  
Year ended April 30, 2018   $ 11,521,295             1,714,306             13,235,601